South Africa has the world’s largest ARV program, currently providing treatment to around 2.7 million people in the public health sector and over 150,000 in the private sectors (as at December 2013).
“Ketlaphela Pharmaceutical SOC Ltd ‘‘Ketlaphela’’ was created in response to the cabinet’s directive for the country to have its own State owned pharmaceutical company. Increasing local manufacturing to decrease reliance and risks associated with high level of imports for this important sector has been a priority for government that ultimately led to the call for the Ketlaphela Project.
The State owned pharmaceutical company is premised on supplying South African manufactured Active Pharmaceutical Ingredients (APIs) and final formulated medical products mainly for communicable diseases such as HIV/AIDS, Tuberculosis, and Malaria and later non-communicable diseases”. Product availability and hence security of supply will likely improve due to a closer working relationship between the Dept. of Health and a state owned company.
The socio-economic benefits of Ketlaphela are job creation, technology transfer, reduction in the balance of Trade in pharmaceuticals through effective localization, capacity building and improving the affordability of treatments for high burden diseases, such as HIV, Tuberculosis and some non-communicable diseases.
Our vision is to be a leader in the delivery of quality and affordable medicines to the local market.
• To be the preferred supplier of local medicine
• Deliver on our promises, safely and in an
environmentally responsible manner.
• Driving growth through Excellence, Innovation,
Performance and Customer Focus.
Ketlaphela Pharmaceuticals Leadership
Mr Brian Mphahlele is an au fait Intellectual Property management, Commercialisation and Business Development Executive. In the period that he has been in this field, he has done negotiated & concluded a number of royalty bearing patent and know-how license deals across various industrial sectors with local and international companies (covering legal/technological/financial dimensions). He has negotiated patent pooling/collaboration agreements for joint exploitation with international organisations. He served as Chairman of the board of UViRCO Technologies (Pty) Ltd and as Non-Executive Director for NTP Radioisotopes SOC Ltd. He graduated in Science (Microbiology and Biotechnology) and Law (LLB) from Wits University and University of South Africa respectively. Mr Mphahlele also completed an accelerated executive education program presented by faculty members from University of Emory Goizueta Business School.
Motheo Moatshe is executive director of Ketlaphela SOC Ltd and holds degrees in chemistry, marketing and economics and has over 20 years of experience in the chemical industry. He has held various management positions in leading local and global chemicals companies including appointments in Europe and Middle East and has conducted business in all major chemicals markets around the world. Motheo is currently an Executive of Pelchem SOC.
Mr Ivan Radebe is the Managing Director of Ketlaphela Pharmaceuticals SOC Ltd and serves as an executive director on the board of directors. He is a member of the Engineering Council of South Africa (ECSA) and the Institute of Directors in Southern Africa (IoDSA). He is an internationally trained and experienced executive with expertise in Asset Maintenance & Management, Infrastructure Project Development, Sales & Marketing, Operations & Strategic Leadership. He previously worked for PetroSA, National Department of Public Works, General Electric, Eskom and NTP Europe in Belgium. He has Masters in Strategy and Project Management from Université Paris 1 Panthéon-Sorbonne, a B-Eng(Honors)- Electrical/Electronics from the University Teknologi PETRONAS, National Diploma in Electrical Engineering from Vaal University of Technology, MDP from UNISA and EDP from University of Stellenbosch Business School.